About Paeptor Pharma
Painceptor develops peripherallyactive pharmaceuticals for the treatment and management of pain. Per the company, Painceptors researchers and industrial collaborators have advanced a series of highly selective organic molecules which will alleviate pain in a number of debilitating untreated diseases. PainCeptors therapeutics relieve pain by intercepting tissue specific pain at the source and promoting a receptive physiological environment for relief of chronic and acute pain.
Missing: Paeptor Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Paeptor Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Paeptor Pharma Frequently Asked Questions (FAQ)
When was Paeptor Pharma founded?
Paeptor Pharma was founded in 2003.
Where is Paeptor Pharma's headquarters?
Paeptor Pharma's headquarters is located at 7150 Albert-Einstein, Saint-Laurent.
What is Paeptor Pharma's latest funding round?
Paeptor Pharma's latest funding round is Other Investors.
Who are the investors of Paeptor Pharma?
Investors of Paeptor Pharma include Lumira Ventures, Canadian Medical Discoveries Fund, Lothian Partners, Coller Capital, T2C2 Capital and 5 more.
Who are Paeptor Pharma's competitors?
Competitors of Paeptor Pharma include Ardelyx, Intercept Pharmaceuticals, CoLucid Pharmaceuticals, Afferent Pharmaceuticals, Spinifex and 12 more.
Compare Paeptor Pharma to Competitors
Ameritox is the nation's leader in pain prescription monitoring.
Neurotide is developing pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.
NeurAxon is discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Neorphys is a specialty pharma company focusing on safe pain relief, especially visceral pain management.
is engaged in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The company's mission is the discovery, development and commercialization of therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma.
Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.